Pathos AI to collaborate with Bristol Myers Squibb and Tempus AI on neurological disease drug development
TEM Tempus AI Inc
$63.81 -5.83%
View chart & analysis → - 1Pathos AI is collaborating with Bristol Myers Squibb and Tempus AI to develop AI tools for the development of drugs for Alzheimer's disease and other neurological diseases.
- 2Pathos AI's enterprise value reached approximately $3 billion through its $237 million Series E funding round.
- 3Pathos AI will use Tempus data for five years based on a $55 million data licensing agreement.
So what's the key point?
Pathos AI is teaming up with other companies to develop AI tools for making neurological disease drugs. The company's value reached approximately $3 billion after receiving $237 million in investment.
Source Reuters · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.